Clinical and genetic characteristics of type 2 diabetes with and without GAD antibodies.

The aim of the study was 1) to establish the prevalence of GAD antibodies (GADab) in a population-based study of type 2 diabetes in western Finland, 2) to genetically and phenotypically characterize this subgroup, and 3) to provide a definition for latent autoimmune diabetes in adults (LADA). The prevalence of GADab was 9.3% among 1,122 type 2 diabetic patients, 3.6% among 558 impaired glucose tolerance (IGT) subjects, and 4.4% among 383 nondiabetic control subjects. Islet antigen 2 antibodies (IA2ab) or islet cell antibodies were detected in only 0.5% of the GADab- patients. The GADab+ patients had lower fasting C-peptide concentrations (median [interquartile range]: 0.46 [0.45] vs. 0.62 [0.44] nmol/l, P = 0.0002) and lower insulin response to oral glucose compared with GADab- patients. With respect to features of the metabolic syndrome, the GADab+ patients had lower systolic (140 [29.1] vs. 148 [26.0] mmHg, P = 0.009) and diastolic (79.2 [17.6] vs. 81.0 [13.1] mmHg, P = 0.030) blood pressure values, as well as lower triglyceride concentrations (1.40 [1.18] vs. 1.75 [1.25] mmol/l, P = 0.003). GADab+ men had a lower waist-to-hip ratio compared with GADab- patients. Compared with GADab- patients and control subjects, the GADab+ patients had an increased frequency HLA-DQB1*0201/0302 (13 vs. 4%; P = 0.002) and other genotypes containing the *0302 allele (22 vs. 12%; P = 0.010). However, the frequency of these high-risk genotypes was significantly lower in GADab+ type 2 patients than in type 1 diabetes of young or adult onset (0201/0302 or 0302/X: 36 vs. 66 vs. 64%, P < 0.001). The GADab+ type 2 group did not differ from control subjects with respect to genotypes containing the protective DQB1-alleles *0602 or *0603, nor with respect to the type 1 high-risk genotype in the IDDM1 (Hph1 +/+). We conclude that GADab+ patients differ from both GADab- type 2 diabetic patients and type 1 diabetic patients with respect to beta-cell function, features of the metabolic syndrome, and type 1 diabetes susceptibility genes. Further, we propose that LADA be defined as GADab positivity (>5 relative units) in patients older than 35 years at onset of type 2 diabetes.

[1]  W. Irvine,et al.  CLINICAL AND PATHOGENIC SIGNIFICANCE OF PANCREATIC-ISLET-CELL ANTIBODIES IN DIABETICS TREATED WITH ORAL HYPOGLYCÆMIC AGENTS , 1977, The Lancet.

[2]  L. Andersson,et al.  Antibodies Against Gastrointestinal Carcinoid Tumors in IDDM , 1989, Diabetes.

[3]  T. Saruta,et al.  Radioimmunoassay detects the frequent occurrence of autoantibodies to the Mr 65,000 isoform of glutamic acid decarboxylase in Japanese insulin-dependent diabetes. , 1994, Autoimmunity.

[4]  A. Kimura.  Eleventh international histocompatibility workshop reference protocol for the HLA DNA-typing technique , 1992 .

[5]  Å. Lernmark,et al.  Quantitative assay using recombinant human islet glutamic acid decarboxylase (GAD65) shows that 64K autoantibody positivity at onset predicts diabetes type. , 1993, The Journal of clinical investigation.

[6]  M. Fantone,et al.  Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus , 1997, Diabetes Care.

[7]  L. Groop,et al.  Metabolic Consequences of a Family History of NIDDM (The Botnia Study): Evidence for Sex-Specific Parental Effects , 1996, Diabetes.

[8]  J. Stengård,et al.  Genetic susceptibility to non-insulin dependent diabetes mellitus and glucose intolerance are located in HLA region. , 1993, BMJ.

[9]  J. Ilonen,et al.  A comparison of childhood and adult type I diabetes mellitus. , 1989, The New England journal of medicine.

[10]  L. Groop,et al.  Organ-Specific Autoimmunity and HLA-DR Antigens as Markers for β-Cell Destruction in Patients With Type II Diabetes , 1988, Diabetes.

[11]  J. Todd,et al.  A genome-wide search for human type 1 diabetes susceptibility genes , 1994, Nature.

[12]  L. Groop,et al.  Antibodies to Glutamic Acid Decarboxylase Reveal Latent Autoimmune Diabetes Mellitus in Adults With a Non—Insulin-Dependent Onset of Disease , 1993, Diabetes.

[13]  K. Gabbay,et al.  The HOXD8 Locus (2q31) is Linked to Type I Diabetes: Interaction with Chromosome 6 and 11 Disease Susceptibility Genes , 1995, Diabetes.

[14]  F. Pociot,et al.  Linkage of type I diabetes to 15q26 (IDDM3) in the Danish population , 1996, Human Genetics.

[15]  N. Maclaren,et al.  Intrafamilial and case-control association analysis of D2S152 in insulin-dependent diabetes. , 1995, Autoimmunity.

[16]  Å. Lernmark,et al.  β-Cell Function in Relation to Islet Cell Antibodies During the First 3 Yr After Clinical Diagnosis of Diabetes in Type II Diabetic Patients , 1993, Diabetes Care.

[17]  P. Bingley,et al.  Combined use of autoantibodies (IA-2 autoantibody, GAD autoantibody, insulin autoantibody, cytoplasmic islet cell antibodies) in type 1 diabetes: Combinatorial Islet Autoantibody Workshop. , 1998, Diabetes.

[18]  S. Nagataki,et al.  Clinical evaluation of non-insulin-dependent diabetes mellitus patients with autoantibodies to glutamic acid decarboxylase. , 1996, Journal of autoimmunity.

[19]  J. Todd,et al.  Susceptibility to human type 1 diabetes at IDDM2 is determined by tandem repeat variation at the insulin gene minisatellite locus , 1995, Nature Genetics.

[20]  N. Nakamura,et al.  Antibodies to Glutamic Acid Decarboxylase in Japanese Diabetic Patients with Secondary Failure of Oral Hypoglycaemic Therapy , 1997, Diabetic medicine : a journal of the British Diabetic Association.

[21]  J. Todd,et al.  Saturation multipoint linkage mapping of chromosome 6q in type 1 diabetes. , 1996, Human molecular genetics.

[22]  R. Holman,et al.  UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes , 1997, The Lancet.

[23]  J. Karam,et al.  A Polymorphic Locus Near the Human Insulin Gene Is Associated with Insulin-dependent Diabetes Melliitus , 1984, Diabetes.

[24]  P. Fernlund,et al.  Islet Cell Antibodies at Diagnosis, But Not Leanness, Relate to a Better Cardiovascular Risk Factor Profile 5 Years After Diagnosis of NIDDM , 1996, Diabetes Care.

[25]  E. Lander,et al.  Characterization of the MODY3 phenotype. Early-onset diabetes caused by an insulin secretion defect. , 1997, The Journal of clinical investigation.

[26]  L. Groop,et al.  Chronic diabetic complications in patients with MODY3 diabetes , 1998, Diabetologia.

[27]  P. Zimmet,et al.  Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation , 1998, Diabetic medicine : a journal of the British Diabetic Association.

[28]  J. Ilonen,et al.  Rapid HLA-DQB1 Genotyping for Four Alleles in the Assessment of Risk for IDDM in the Finnish Population , 1996, Diabetes Care.

[29]  J. Nerup,et al.  HLA associations in insulin-dependent diabetes: search for heterogeneity in different groups of patients from a homogeneous population. , 2008, Tissue antigens.

[30]  W. Scherbaum,et al.  Distinct Genetic and Immunological Features in Patients With Onset of IDDM Before and After Age 40 , 1997, Diabetes Care.

[31]  Å. Lernmark,et al.  Beta-cell function in relation to islet cell antibodies during the first 3 yr after clinical diagnosis of diabetes in type II diabetic patients. , 1993, Diabetes care.

[32]  M. James,et al.  Genetic mapping of a susceptibility locus for insulin-dependent diabetes mellitus on chromosome llq , 1994, Nature.

[33]  J. Ilonen,et al.  Effect of polymorphism in the insulin gene region on IDDM susceptibility and insulin secretion ** , 1996, European journal of clinical investigation.

[34]  L. Groop,et al.  Islet Cell Antibodies Identify Latent Type I Diabetes in Patients Aged 35–75 Years at Diagnosis , 1986, Diabetes.

[35]  J. Todd,et al.  Linkage disequilibrium mapping of a type 1 diabetes susceptibility gene (IDDM7) to chromosome 2q31–q33 , 1995, Nature Genetics.

[36]  L. Groop,et al.  GAD Antibodies in NIDDM: Ten-year follow-up from the diagnosis , 1995, Diabetes Care.